Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PLAUR_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PLAUR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PLAUR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PLAUR_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLAUR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PLAUR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLAUR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLAUR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PLAUR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLAUR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLAUR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:005109934 | Thyroid | ATC | positive regulation of binding | 103/6293 | 173/18723 | 2.19e-12 | 9.05e-11 | 103 |
GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
GO:200124333 | Thyroid | ATC | negative regulation of intrinsic apoptotic signaling pathway | 63/6293 | 98/18723 | 4.97e-10 | 1.33e-08 | 63 |
GO:0010821112 | Thyroid | ATC | regulation of mitochondrion organization | 82/6293 | 144/18723 | 7.15e-09 | 1.54e-07 | 82 |
GO:0038127111 | Thyroid | ATC | ERBB signaling pathway | 71/6293 | 121/18723 | 1.31e-08 | 2.69e-07 | 71 |
GO:0007173111 | Thyroid | ATC | epidermal growth factor receptor signaling pathway | 63/6293 | 108/18723 | 1.15e-07 | 1.92e-06 | 63 |
GO:0045785210 | Thyroid | ATC | positive regulation of cell adhesion | 194/6293 | 437/18723 | 1.40e-06 | 1.75e-05 | 194 |
GO:005110133 | Thyroid | ATC | regulation of DNA binding | 64/6293 | 118/18723 | 3.10e-06 | 3.54e-05 | 64 |
GO:004328133 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 102/6293 | 209/18723 | 3.61e-06 | 4.03e-05 | 102 |
GO:0008637112 | Thyroid | ATC | apoptotic mitochondrial changes | 59/6293 | 107/18723 | 3.69e-06 | 4.10e-05 | 59 |
GO:005254734 | Thyroid | ATC | regulation of peptidase activity | 200/6293 | 461/18723 | 6.25e-06 | 6.52e-05 | 200 |
GO:200011633 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity | 111/6293 | 235/18723 | 9.41e-06 | 9.41e-05 | 111 |
GO:001082216 | Thyroid | ATC | positive regulation of mitochondrion organization | 43/6293 | 74/18723 | 1.30e-05 | 1.25e-04 | 43 |
GO:190118415 | Thyroid | ATC | regulation of ERBB signaling pathway | 45/6293 | 79/18723 | 1.68e-05 | 1.55e-04 | 45 |
GO:004205814 | Thyroid | ATC | regulation of epidermal growth factor receptor signaling pathway | 42/6293 | 73/18723 | 2.29e-05 | 2.02e-04 | 42 |
GO:004315433 | Thyroid | ATC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 43/6293 | 78/18723 | 7.43e-05 | 5.63e-04 | 43 |
GO:003410933 | Thyroid | ATC | homotypic cell-cell adhesion | 48/6293 | 90/18723 | 8.92e-05 | 6.59e-04 | 48 |
GO:200011733 | Thyroid | ATC | negative regulation of cysteine-type endopeptidase activity | 46/6293 | 86/18723 | 1.13e-04 | 8.08e-04 | 46 |
GO:0001836111 | Thyroid | ATC | release of cytochrome c from mitochondria | 34/6293 | 59/18723 | 1.29e-04 | 9.10e-04 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLAUR | SNV | Missense_Mutation | rs750492027 | c.829N>A | p.Ala277Thr | p.A277T | Q03405 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.198N>G | p.Ser66Arg | p.S66R | Q03405 | protein_coding | deleterious(0) | benign(0.284) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PLAUR | insertion | In_Frame_Ins | novel | c.389_390insTCCCCTGGCCCCCATAGGGCGTCCAAAGGATGA | p.Gly130_Arg131insProLeuAlaProIleGlyArgProLysAspAsp | p.G130_R131insPLAPIGRPKDD | Q03405 | protein_coding | | | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLAUR | SNV | Missense_Mutation | | c.346G>A | p.Glu116Lys | p.E116K | Q03405 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PLAUR | SNV | Missense_Mutation | rs756038834 | c.814N>A | p.Ala272Thr | p.A272T | Q03405 | protein_coding | tolerated(0.3) | benign(0.042) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.118G>T | p.Ala40Ser | p.A40S | Q03405 | protein_coding | tolerated(0.21) | benign(0.028) | TCGA-AF-4110-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | SD |
PLAUR | SNV | Missense_Mutation | novel | c.979N>A | p.Leu327Met | p.L327M | Q03405 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.533) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.389N>A | p.Gly130Asp | p.G130D | Q03405 | protein_coding | deleterious(0.01) | benign(0.264) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.668N>T | p.Ser223Ile | p.S223I | Q03405 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.252N>T | p.Lys84Asn | p.K84N | Q03405 | protein_coding | deleterious(0.03) | benign(0.213) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | ADENOVIRAL VECTOR | | 12955075 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | UROKINASE | UROKINASE | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | RECOMBINANT INTERFERON GAMMA | | 8049441 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | G-CSF | FILGRASTIM | 15747404 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | MCP-2 | | 12138365 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | DIPHTHERIA TOXIN | | 11959893 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | Ruxolitinib | RUXOLITINIB | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | PHORBOL MYRISTATE ACETATE | | 9531044 |